PharmaTher Holdings Ltd (QB) (PHRRF) Quote

$PHRRF Christmas Special - FDA provided preliminary responses to questions contained in the clarification only post-CRL meeting scheduled for December 2, 2024

PharmaTher has decided to cancel the meeting as the FDA preliminary responses were satisfactory and do not require further discussion

PharmaTher initiated activities to address the MINOR deficiencies cited in the CRL

https://finance.yahoo.com/news/pharmather-announces-fda-drug-application-130000255.html

$PHRRF chart looking good for a breakout? https://stockcharts.com/sc3/ui/?s=PHRRF

$PHRRF News : PharmaTher Announces Update on FDA New Drug Application for Ketamine
https://finance.yahoo.com/news/pharmather-announces-fda-drug-application-130000255.html

$PHRRF Buy average from @barchart
https://www.barchart.com/stocks/quotes/PHRRF/opinion

$PHRRF EMA Analysis

$PHRRF FDA New Drug Application for Ketamine goal date of October 29, 2024.
https://finance.yahoo.com/news/pharmather-announces-fda-drug-application-120000733.html

$PHRRF Pivot indicator looking good here - https://schrts.co/DrQWIMBS

$PHRRF buy average from barchart https://www.barchart.com/stocks/quotes/PHRRF/opinion

This application is good for Parkinsons Dyskinesia.This could be big because the patient could apply the patch themselves.GLTA

$PHRRF 🔓⤵️ potential FDA Approval of #Ketamine on or about October 29th could unlock the advancement of its 6 FDA orphan designations for Ketamine.

Visit http://pharmather.com

$PHRRF $PHRM

$PHRRF Technical chart

Nice volume and move up today

Nothing to do, but sit and wait. I think the fact that FDA isn't requesting further data is a positive. We'll find out soon enough. I believe if FDA wants to regulate Ketamine, they need to be willing to approve generic producers, who are doing it right, through the regulatory process.

$PHRRF #BreakingNews @Pharmather_Inc Announces Update on FDA New Drug Application for Ketamine https://finance.yahoo.com/news/pharmather-announces-fda-drug-application-120000733.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

$PHRRF Chart looking good > https://www.centralcharts.com/en/2254353-newscope-cap-corp-phrrf/charts

$PHRRF Breakout chart https://stockcharts.com/sc3/ui/?s=PHRRF

$PHRRF bottoming volume support level view. maybe
https://schrts.co/EFvhjhrE

Definitely looking interesting....What kinda $market would they be in if approved

$PHRRF The Company aims to submit its responses to the FDA by the end of this week. There can be no assurance the GDUFA goal date will be met. Should the goal date not be met, the FDA would provide a Complete Response Letter to the Company to address the responses, provide additional feedback, if any, and assign an appropriate goal date. The Company is prepared to address potential FDA requests and concerns immediately and will update shareholders as they occur.
https://finance.yahoo.com/news/pharmather-provides-priority-original-abbreviated-120000352.html

Way undervalued. Only been saying it years now.

Adding. Way cheap now!!!!

Was info leaked on fda decesion or just market makers screwing with retail?

thanjs for the valuable information

Good way to end the week

Nice day

PHRRF looking good. GLTA

Probably run up to FDA decision in April 2024.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
https://finance.yahoo.com/news/pharmather-provides-priority-original-abbreviated-130000660.html

Fabio Chianelli, CEO of PharmaTher, commented: “We believe 2024 will be a transformative year for PharmaTher with the expected FDA approval of ketamine having an assigned goal date for approval on April 29, 2024. In anticipation of a potential FDA approval, we are focusing on the commercial scale-up of ketamine in the U.S. and seeking additional international approvals.”

Why the volume increase lately?

Nice volume recently. GLTa shareholders

What???

Bid 10 cents

$PHRRF 80% strong buy opportunity from @Barchart
https://www.barchart.com/stocks/quotes/PHRRF/opinion

Fabio Chianelli, CEO of PharmaTher, commented: “We believe 2024 will be a transformative year for PharmaTher with the expected FDA approval of ketamine having an assigned goal date for approval on April 29, 2024. In anticipation of a potential FDA approval, we are focusing on the commercial scale-up of ketamine in the U.S. and seeking additional international approvals.”

https://finance.yahoo.com/news/pharmather-provides-expected-fda-approval-123000873.html

PHRRF continuing that nice climb upwards today. GLTA shareholders

Looking good.

52 week high again today. GLTA shareholders

52 week high today! Nice

$PHRRF Strong buy from technical analysis from tradingview https://www.tradingview.com/symbols/OTC-PHRRF/technicals/

I think we will do well here,it seems like a sure thing that we will be marketing this in early 2024.GLTA

https://www.globenewswire.com/news-release/2023/09/27/2750259/0/en/PharmaTher-Announces-FDA-Acceptance-As-a-Priority-Original-Abbreviated-New-Drug-Application-for-KETARX-Ketamine.html

$PHRRF $PHRM The Company’s lead product is KETARX™ (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications.
@RexWiggins12
https://thenew.money/article/hedge-fund-billionaire-steve-cohen-is-betting-on-psychedelics

$PHRRF News Out! PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
https://finance.yahoo.com/news/pharmather-submits-priority-original-abbreviated-113000329.html

$PHRRF Update : September 2023 Corporate Presentation https://www.pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf
#Ketamine #psychedelics #cepharanthine $PHRM $PHRM.C

$PHRRF
Transdermal Medical Patch Market worth $10.79 Billion by 2028 - Exclusive Report by The Insight Partners
Global transdermal medical patch market is growing at a CAGR of 4% from 2023 to 2028.
@RexWiggins12

https://globenewswire.com/news-release/2023/09/04/2736780/0/en/Transdermal-Medical-Patch-Market-worth-10-79-Billion-by-2028-Exclusive-Report-by-The-Insight-Partners.html

Certainly encouraging.

Interesting that PHRRF and RVVTF mentioned in the article below. GLTA

From the article below:

“In February 2023, Revive Therapeutics Ltd. entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine ("MDMA") using PharmaTher's novel microneedle patch ("MN-Patch") delivery technology. The MDMA MN-Patch enables flexible drug load capacity and combinations, controlled released delivery, and the ability to present desired pharmacokinetic and safety profiles, overcoming the potential obstacles of oral dosing.”

GLTA shareholders

https://www.globenewswire.com/news-release/2023/09/04/2736780/0/en/Transdermal-Medical-Patch-Market-worth-10-79-Billion-by-2028-Exclusive-Report-by-The-Insight-Partners.html#:~:text=Transdermal%20Medical%20Patch%20Market%20in,published%20by%20The%20Insight%20Partners.